Rhumbline Advisers Makes New Investment in INmune Bio, Inc. (NASDAQ:INMB)

Rhumbline Advisers purchased a new stake in INmune Bio, Inc. (NASDAQ:INMB) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 13,773 shares of the company’s stock, valued at approximately $121,000. Rhumbline Advisers owned 0.07% of INmune Bio as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of INMB. Bank of New York Mellon Corp lifted its stake in INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares in the last quarter. Westside Investment Management Inc. grew its position in shares of INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after purchasing an additional 10,950 shares in the last quarter. Finally, Fermata Advisors LLC increased its holdings in shares of INmune Bio by 8.5% in the second quarter. Fermata Advisors LLC now owns 34,140 shares of the company’s stock worth $301,000 after purchasing an additional 2,689 shares during the period. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on INMB. Raymond James initiated coverage on INmune Bio in a report on Friday. They set an “outperform” rating and a $18.00 price objective for the company. Scotiabank assumed coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 target price for the company.

INmune Bio Price Performance

Shares of INmune Bio stock opened at $5.39 on Tuesday. The stock has a market capitalization of $106.62 million, a P/E ratio of -2.81 and a beta of 1.86. INmune Bio, Inc. has a one year low of $4.81 and a one year high of $14.74. The business’s 50 day simple moving average is $6.73 and its two-hundred day simple moving average is $8.75.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%.

Insider Buying and Selling at INmune Bio

In other INmune Bio news, CEO Raymond Joseph Tesi purchased 15,380 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the transaction, the chief executive officer now directly owns 1,554,106 shares in the company, valued at approximately $9,915,196.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Raymond Joseph Tesi purchased 15,380 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the completion of the acquisition, the chief executive officer now directly owns 1,554,106 shares in the company, valued at approximately $9,915,196.28. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO David J. Moss purchased 10,000 shares of INmune Bio stock in a transaction that occurred on Monday, September 30th. The shares were purchased at an average cost of $5.29 per share, with a total value of $52,900.00. Following the transaction, the chief financial officer now directly owns 1,285,869 shares of the company’s stock, valued at $6,802,247.01. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 33,070 shares of company stock valued at $200,087. 35.20% of the stock is currently owned by company insiders.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.